<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Our prior study has been reported the formation of the oxidized <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (oxLDL)/β(2)-glycoproteinI (β(2)-GPI)/autoantibody complex facilitated the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) process </plain></SENT>
<SENT sid="1" pm="."><plain>The domain V of β(2)-GPI binds to the negatively charged molecules, e.g. 7-ketochoresteryl-9-caboxynonanoate (oxLig-1) derived from the oxLDL and mediates the interaction between oxLDL and β(2)-GPI </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, the oxLig-1/β(2)-GPI/anti-β(2)-GPI Ab (WB-CAL-1) model was established </plain></SENT>
<SENT sid="3" pm="."><plain>The recombinant domain V of β(2)-GPI (rβ(2)-GPI DV) expressed in Escherichia coli competitively inhibits the interaction between ��(2)-GPI and oxLig-1 in the enzyme-linked immunoassay </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, the rβ(2)-GPI DV significantly inhibits the formation of the oxLig-1/β(2)-GPI/autoantibody complex in an APS patient </plain></SENT>
<SENT sid="5" pm="."><plain>The present work suggests a novel possibility that rβ(2)-GPI DV could be used to inhibit the formation of oxLDL/β(2)-GPI/autoantibody complex, and give us a hint for the development of new therapeutic strategies to prevent the APS process </plain></SENT>
</text></document>